ACH

SEC Filing Summary: Owens & Minor, Inc. (10-K)

Business Context and Reporting Period

Company: Owens & Minor, Inc. (Note: Input metadata referenced "Accendra Health Inc," but the filing text is for Owens & Minor, Inc.)
Period: Year ended December 31, 2005
Business Overview: The nation's leading distributor of national name-brand medical and surgical supplies and a healthcare supply-chain management company. The company distributes approximately 130,000 products to roughly 4,000 healthcare providers, primarily acute-care hospitals and integrated healthcare networks (IHNs). In January 2005, the company expanded into direct-to-consumer distribution via the acquisition of Access Diabetic Supply, LLC.

Key Financial Metrics (2005)

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 7% to $4.82 billion, driven by higher sales volume to existing customers, new customer acquisitions, and the contribution of the new direct-to-consumer diabetic supply business (Access), which accounted for approximately one-fifth of the revenue increase.
• Profitability: Net income rose 6% to $64.4 million. Operating earnings remained flat as a percentage of revenue (2.4%) due to offsetting factors: benefits from the higher-margin direct-to-consumer segment were counterbalanced by lower supplier incentives and a $3.5 million software impairment charge.
• Cash Flow: Operating cash flow more than doubled to $135.4 million, significantly aided by the timing of inventory payments and strong working capital management.
• Acquisitions: The company spent approximately $71.6 million on acquisitions in 2005, primarily for Access Diabetic Supply ($58.8 million) and smaller software firms to enhance its OMSolutions unit.
• Disruptions: The company incurred approximately $2.0 million in negative impact due to Hurricanes Katrina and Rita, resulting in lost sales and higher delivery costs, though facilities remained undamaged.

Guidance, Outlook, Risks, and Contingencies

• Outlook: Management expects competitive pricing pressure to continue. The company is pursuing margin initiatives through value-added services (OMSolutions, PANDAC) and private label products (MediChoice) to counteract lower supplier incentives.
• Accounting Changes: The company must adopt SFAS 123R (Share-Based Payment) effective January 1, 2006, which is expected to have a material effect on results of operations by requiring fair value recognition of stock-based compensation.
• Key Risks:
  • Customer Concentration: 72% of revenue comes from members of three major Group Purchasing Organizations (Novation, Broadlane, Premier). Loss of a GPO relationship could materially affect results.
  • Supplier Dependence: The top 10 suppliers accounted for 60% of revenue. Changes in supplier terms or direct-to-hospital sales by suppliers pose a risk.
  • Regulatory/Reimbursement: Changes in Medicare reimbursement rates or healthcare legislation could adversely affect the direct-to-consumer diabetic business.
• Contingencies: The IRS proposed disallowing certain LIFO inventory valuation deductions effective 2001. If unsuccessful in its appeal, the company faces a potential tax deficiency of approximately $41.6 million plus interest. No reserve has been established.

Investor Verification Checklist

• IRS LIFO Dispute: Verify the status of the IRS appeal regarding LIFO inventory valuation and the potential $41.6 million tax liability.
• Access Diabetic Supply Integration: Monitor the performance and margin sustainability of the new direct-to-consumer segment, particularly regarding Medicare reimbursement rates.
• Software Impairment: Review the details of the $3.5 million software impairment charge and the status of technology modernization efforts.
• Stock-Based Compensation Impact: Assess the projected impact of SFAS 123R adoption on 2006 net income and EPS.
• GPO Contract Renewals: Track the renewal status of contracts with Novation, Broadlane, and Premier, which represent the majority of revenue.